Acorda Therapeutics (NASDAQ:ACOR) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.
Risk and Volatility
Acorda Therapeutics has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 3.54, indicating that its share price is 254% more volatile than the S&P 500.
This table compares Acorda Therapeutics and Genetic Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Acorda Therapeutics and Genetic Technologies’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Acorda Therapeutics||$471.43 million||0.70||$33.68 million||$1.82||3.79|
|Genetic Technologies||$140,000.00||78.45||-$4.23 million||N/A||N/A|
Acorda Therapeutics has higher revenue and earnings than Genetic Technologies.
This is a summary of current ratings and price targets for Acorda Therapeutics and Genetic Technologies, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Acorda Therapeutics presently has a consensus target price of $20.22, indicating a potential upside of 193.50%. Given Acorda Therapeutics’ higher probable upside, analysts clearly believe Acorda Therapeutics is more favorable than Genetic Technologies.
Acorda Therapeutics beats Genetic Technologies on 6 of the 9 factors compared between the two stocks.
About Acorda Therapeutics
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
About Genetic Technologies
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.